Danahervs.Illumina
DHR vs ILMN · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 3.8× larger than Illumina by market cap; Danaher trades at the lower P/E (37.3 vs 47.1); year to date, Illumina leads (+104.1% vs −4.6%).
Side by side
| DHR | ILMN | |
|---|---|---|
| Market cap | $149B | $38.8B |
| Price | $217.46 | $264.57 |
| Today | −0.5% | −1.2% |
| Return YTD | −4.6% | +104.1% |
| Return 1Y | +4.7% | +177.0% |
| Since June 26, 2026 | +10.8% | +49.9% |
| P/E | 37.3 | 47.1 |
| P/S | 5.9 | 8.6 |
| P/B | 2.8 | 13.7 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
DanaherDHR
Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.
Full DHR profile →IlluminaILMN
DNA sequencing machines and the reagents they consume, for research and clinical genomics.
Full ILMN profile →More DHR & ILMN comparisons
Other head-to-heads in the Life science tools segment.